Project Details
Targeting of cancer-associated fibroblasts with drug-loaded polymeric nanoparticles to improve im-mune therapy for primary and secondary liver tumors (B17*)
Subject Area
Immunology
Term
since 2021
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 213555243
Nanoparticles are decorated with CAF-targeting ligands, loaded with CAF-modulating drugs (e.g. anti-TGFβ1 siRNA, AT1R-antagonists) and tested in vitro (in i.a. tumor organoids) to select promising candidates for therapeutic in vivo experiments. After biodistribution and tumor tissue accumulation of the drug-loaded na-noparticles have been assessed by multimodal imaging methods, therapeutic antitumor effects of the vali-dated drug-loaded nanoparticles are studied in relevant murine liver tumor models, whereby i.a. RNA- and proteomics are applied to gain insight into therapeutic mechanisms.
DFG Programme
Collaborative Research Centres
Applicant Institution
Johannes Gutenberg-Universität Mainz
Project Heads
Dr. Mustafa Diken; Dr. Leonard Kaps; Professor Dr. Twan Lammers